ASSOCIATION BETWEEN BILIARY DISEASE, INCLUDING ACUTE CHOLECYSTITIS,AND DIPEPTIDYL PEPTIDASE 4 INHIBITORS USE IN PATIENTS WITH TYPE 2 DIABETES MELITTUS
BMC Journal of Medical Sciences · 29.06.2026 · 7 (1) · 82-86
DOI: 10.70905/bmcj.07.01.0641 ↗Kurz gefasst
Fachartikel in der Zeitschrift BMC Journal of Medical Sciences, online erschienen am 29.06.2026. Verfasst von Ammara Riaz Chohan und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Type 2 diabetes mellitus (T2DM) is a global health challenge associated with multiple significant complications. Recent studies suggest that use of dipeptidyl peptidase 4 (DPP-4) inhibitors, may be linked to acute cholecystitis and biliary dysfunction. Understanding this association is important, as biliary complications may adversely affect patient outcomes.
Objective
To explore the association between biliary disease, including acute cholecystitis, in patients with type 2 diabetes mellitus treated with DPP-4 inhibitors. Material and Methods: This cross-sectional study was conducted between Nov 2022 to August 2024 at PAF Hospital, Islamabad. The study population had two qual groups of 350 patients each comprising type 2 diabetic patients receiving DPP-4 inhibitors and those receiving other ant diabetic medications. The data regarding demographic characteristics and biliary outcomes were collected from their medical records using a structured questionnaire and analyzed using SPSS version 25 to find the association between biliary disease and use of DPP4 inhibitors.
Results
Patients receiving DPP-4 inhibitors showed a significantly higher frequency of acute cholecystitis compared to those receiving other antidiabetic medications (16.0% vs 10.0%, p=0.027; OR=1.71, 95% CI: 1.09–2.68). There were also higher frequencies of gallstones (22.0% vs 16.0%, p=0.153; OR=1.48, 95% CI: 0.99–2.20)and biliary sludge (24.0% vs 18.3%, p=0.076; OR=1.41, 95% CI: 0.97–2.05)in the DPP-4 inhibitor group; however, these differences were not statistically significant.
Conclusion
Our findings suggests an association between use of DPP-4 inhibitors and a higher frequency of acute cholecystitis and biliary disease in patients with type 2 diabetes mellitus, warranting careful monitoring in clinical practice.
Zitieren
APA
Chohan, A. R., Niaz, A., Zara, F., Ishfaq, A., & Mehtab, J. (2026). ASSOCIATION BETWEEN BILIARY DISEASE, INCLUDING ACUTE CHOLECYSTITIS,AND DIPEPTIDYL PEPTIDASE 4 INHIBITORS USE IN PATIENTS WITH TYPE 2 DIABETES MELITTUS. BMC Journal of Medical Sciences, 7(1), 82-86. https://doi.org/10.70905/bmcj.07.01.0641
Vancouver
Chohan AR, Niaz A, Zara F, Ishfaq A, Mehtab J. ASSOCIATION BETWEEN BILIARY DISEASE, INCLUDING ACUTE CHOLECYSTITIS,AND DIPEPTIDYL PEPTIDASE 4 INHIBITORS USE IN PATIENTS WITH TYPE 2 DIABETES MELITTUS. BMC Journal of Medical Sciences. 2026;7(1):82-86. doi:10.70905/bmcj.07.01.0641
BibTeX
@article{Chohan2026,
author = {Chohan, Ammara Riaz and Niaz, Asif and Zara, Farrukh and Ishfaq, Afsheen and Mehtab, Javeria},
title = {ASSOCIATION BETWEEN BILIARY DISEASE, INCLUDING ACUTE CHOLECYSTITIS,AND DIPEPTIDYL PEPTIDASE 4 INHIBITORS USE IN PATIENTS WITH TYPE 2 DIABETES MELITTUS},
journal = {BMC Journal of Medical Sciences},
year = {2026},
volume = {7},
number = {1},
pages = {82--86},
doi = {10.70905/bmcj.07.01.0641}
}
EUVIMED